Sai Life Sciences has announced a leadership move that will shape its Global PR&D strategy as it gears up for the next phase of growth. John Pavey will take on the role of Senior Management Personnel and Head – Global PR&D, effective 1 April 2026, stepping into the position as Dean David Edney retires from the same remit at the close of business on 31 March 2026.
Pavey arrives with more than two decades of global experience in CMC and chemical development, including senior leadership roles at Johnson & Johnson, UCB, and AstraZeneca. His breadth spans API development across the product lifecycle, regulatory approvals, and commercial supply, with expertise in new modalities, digital chemistry, sustainable manufacturing, and Quality by Design. He holds a BA (Hons) in Chemistry from the University of Oxford, a PhD in Organic Chemistry from the University of Liverpool, and has completed postdoctoral research at the University of Cambridge.
The transition underscores Sai Life’s commitment to a globally integrated, science-led R&D engine as it scales. Edney’s retirement marks the end of a chapter in the company’s Global PR&D journey, while Pavey’s background aligns with ambitions to advance new modalities and digital-driven innovations in supply and quality. As Sai Life continues to navigate a dynamic pharma development landscape, leadership continuity in Global PR&D will be crucial for sustaining momentum across products, partnerships, and manufacturing partnerships.